OncoMatch/Clinical Trials/NCT07229729
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
Is NCT07229729 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for non-small cell lung cancer.
Treatment: SHR-A2102 · Adebrelimab · Paclitaxel · Carboplatin · Alomnertinib Mesilate · Furmonertini Mesilate · Osimertinib Mesylate — The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify